| Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial F Carrat, F Bani-Sadr, S Pol, E Rosenthal, F Lunel-Fabiani, A Benzekri, ... Jama 292 (23), 2839-2848, 2004 | 1030 | 2004 |
| Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study L Piroth, J Cottenet, AS Mariet, P Bonniaud, M Blot, P Tubert-Bitter, ... The Lancet Respiratory Medicine 9 (3), 251-259, 2021 | 636 | 2021 |
| Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled … F Ader, M Bouscambert-Duchamp, M Hites, N Peiffer-Smadja, J Poissy, ... The Lancet infectious diseases 22 (2), 209-221, 2022 | 389 | 2022 |
| Fibrinogen and fibronectin binding cooperate for valve infection and invasion in Staphylococcus aureus experimental endocarditis YA Que, JA Haefliger, L Piroth, P François, E Widmer, JM Entenza, ... The Journal of experimental medicine 201 (10), 1627-1635, 2005 | 377 | 2005 |
| Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses H Pan, R Peto, AMH Restrepo, MP Preziosi, V Sathiyamoorthy, QA Karim, ... The Lancet 399 (10339), 1941-1953, 2022 | 297 | 2022 |
| Does hepatitis C virus co-infection accelerate clinical and immunological evolution of HIV-infected patients? L Piroth, M Duong, C Quantin, M Abrahamowicz, R Michardiere, LS Aho, ... Aids 12 (4), 381-388, 1998 | 278 | 1998 |
| Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults with HIV-1: a randomized controlled trial O Launay, D van der Vliet, AR Rosenberg, ML Michel, L Piroth, D Rey, ... Jama 305 (14), 1432-1440, 2011 | 207 | 2011 |
| Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen V Le Moing, G Chêne, MP Carrieri, A Alioum, F Brun-Vézinet, L Piroth, ... Aids 16 (1), 21-29, 2002 | 197 | 2002 |
| Spread of Extended-Spectrum β-Lactamase—Producing Klebsiella pneumoniae: Are β-Lactamase Inhibitors of Therapeutic Value? L Piroth, H Aubé, JM Doise, MV Martin Clinical infectious diseases 27 (1), 76-80, 1998 | 169 | 1998 |
| Association between insulin resistance and hepatitis C virus chronic infection in HIV-hepatitis C virus-coinfected patients undergoing antiretroviral therapy M Duong, JM Petit, L Piroth, M Grappin, M Buisson, P Chavanet, P Hillon, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 27 (3), 245-250, 2001 | 162 | 2001 |
| Persistent COVID-19 symptoms are highly prevalent 6 months after hospitalization: results from a large prospective cohort J Ghosn, L Piroth, O Epaulard, P Le Turnier, F Mentré, D Bachelet, ... Clinical Microbiology and Infection 27 (7), 1041. e1-1041. e4, 2021 | 153 | 2021 |
| Staphylococcus aureus Bloodstream Infection and Endocarditis - A Prospective Cohort Study V Le Moing, F Alla, T Doco-Lecompte, F Delahaye, L Piroth, C Chirouze, ... PloS one 10 (5), e0127385, 2015 | 147 | 2015 |
| Evaluation of the Patient Medication Adherence Questionnaire as a tool for self-reported adherence assessment in HIV-infected patients on antiretroviral regimens M Duong, L Piroth, M Grappin, F Forte, G Peytavin, M Buisson, ... HIV clinical trials 2 (2), 128-135, 2001 | 146 | 2001 |
| Chronic respiratory diseases are predictors of severe outcome in COVID-19 hospitalised patients: a nationwide study G Beltramo, J Cottenet, AS Mariet, M Georges, L Piroth, P Tubert-Bitter, ... European Respiratory Journal 58 (6), 2021 | 137 | 2021 |
| Low 25-OH vitamin D serum levels correlate with severe fibrosis in HIV-HCV co-infected patients with chronic hepatitis B Terrier, F Carrat, G Geri, S Pol, L Piroth, P Halfon, T Poynard, ... Journal of hepatology 55 (4), 756-761, 2011 | 137 | 2011 |
| Vaccine education of medical students: a nationwide cross-sectional survey S Kernéis, C Jacquet, A Bannay, T May, O Launay, P Verger, C Pulcini, ... American journal of preventive medicine 53 (3), e97-e104, 2017 | 135 | 2017 |
| Value of patient self-report and plasma human immunodeficiency virus protease inhibitor level as markers of adherence to antiretroviral therapy: relationship to virologic response M Duong, L Piroth, G Peytavin, F Forte, E Kohli, M Grappin, M Buisson, ... Clinical Infectious Diseases 33 (3), 386-392, 2001 | 135 | 2001 |
| Ten-year incidence and risk factors of bone fractures in a cohort of treated HIV1-infected adults F Collin, X Duval, V Le Moing, L Piroth, F Al Kaied, P Massip, V Villes, ... Aids 23 (8), 1021-1024, 2009 | 130 | 2009 |
| The evolution of hepatitis B virus serological patterns and the clinical relevance of isolated antibodies to hepatitis B core antigen in HIV infected patients L Piroth, C Binquet, M Vergne, A Minello, C Livry, JB Bour, M Buisson, ... Journal of hepatology 36 (5), 681-686, 2002 | 130 | 2002 |
| Risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus-coinfected patients during interferon plus ribavirin-based therapy F Bani-Sadr, F Carrat, S Pol, R Hor, E Rosenthal, C Goujard, P Morand, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 40 (1), 47-52, 2005 | 129 | 2005 |
